Source comparison
TB-500 vs. Direct Libido Modulators: Mechanism Comparison
TB-500 (Thymosin Beta-4) Actin regulation, VEGF upregulation, NF-κB inhibition Indirect: improves endothelial function and NO bioavailability when vascular insufficiency or inflammation present Moderate: documented in vascular recovery studies, not sexual heal
This comparison does not assign a generated winner or score.
- TB-500 (Thymosin Beta-4)
- Actin regulation, VEGF upregulation, NF-κB inhibition
- Indirect: improves endothelial function and NO bioavailability when vascular insufficiency or inflammation present
- Moderate: documented in vascular recovery studies, not sexual health trials
- Relevant only when vascular or inflammatory dysfunction is the root cause. No direct libido pathway engagement
- PT-141 (Bremelanotide)
- Melanocortin receptor (MC3R, MC4R) agonist
- Direct: central nervous system activation of sexual arousal pathways independent of vascular function
- High: FDA-approved for hypoactive sexual desire disorder in premenopausal women
- Addresses desire and arousal through CNS mechanisms. Works regardless of vascular health
- Tadalafil (Cialis)
- PDE5 inhibition. Prevents cGMP degradation
- Direct: enhances NO-mediated vasodilation by prolonging cGMP half-life
- Very High: FDA-approved for erectile dysfunction with extensive RCT data
- Requires functional endothelium and baseline NO production. Amplifies existing signal, doesn't create new vasodilation
- Testosterone Replacement
- Androgen receptor activation
- Direct: restores libido through hypothalamic and limbic system androgen signaling
- Very High: well-established in hypogonadal men
- Addresses hormonal deficiency. Effective when low testosterone is the root cause, irrelevant otherwise
- Apomorphine
- Dopamine D1/D2 receptor agonist
- Direct: central dopaminergic activation of sexual arousal circuits
- Moderate: sublingual formulation approved in EU, withdrawn in US due to side effect profile
- CNS mechanism. Works independently of vascular or hormonal status